This disclosure relates to controlling nitrogen oxides (NOx) emissions for internal combustion engines, and more particularly to an apparatus, system and method for controlling reductant dosing in a selective catalytic reduction (SCR) catalyst.
Emissions regulations for internal combustion engines have become more stringent over recent years. The regulated emissions of NOx and particulates from internal combustion engines are low enough that in many cases the emissions levels cannot be met with improved combustion technologies. Therefore, the use of aftertreatment systems on engines to reduce emissions is increasing. For reducing NOx emissions, NOx reduction catalysts, including selective catalytic reduction (SCR) systems, are utilized to convert NOx (NOx and NO2 in some fraction) to N2 and other compounds. SCR systems utilize a reductant, typically ammonia, to reduce the NOx. The reductant is injected into a combustion engine's exhaust stream upstream of an SCR catalyst. In the presence of the SCR catalyst, the ammonia reacts with the NOx in the exhaust stream to reduce the NOx to less harmful emissions. Currently available SCR systems can produce high NOx conversion rates allowing the combustion technologies to focus on power and efficiency. However, currently available SCR systems also suffer from a few drawbacks.
For example, conventional reductant delivery systems can experience inherent delays and inaccuracies between a commanded dosing rate and the actual dosing rate due to the valve opening and closing characteristics associated with conventional pulsed urea dosage devices. Typical pulsed urea dosage devices pulse at high frequencies for high urea dosing rates and low frequencies for low urea dosing rates. When pulsing at high frequencies, the dosing valve is closed for short durations, but at low frequencies, the dosing valve is closed for long durations. Because the dosing valve is pulsed differently for different dosing rates, the actual dosing rate may be different than the commanded dosing rate.
Additionally, with many conventional SCR systems, the reductant dosing rate depends upon the real-time delivery of reductant into the exhaust stream. But, reductant dosers typically have relatively slow physical dynamics compared to other chemical injectors such as hydrocarbon injectors. Therefore, reliance on real-time reductant delivery may result in inaccuracies between the commanded reductant dosing rate and the actual reductant dosing rate during transient operating conditions due to the physical delays of the reductant dosing system. Generally, reductant dosing delays during transient operating conditions are greater at lower dosing rates and lesser at higher dosing rates. Accordingly, for smaller combustion engines that need smaller amounts of reductant dosing, the dosing system may experience undesirable delays during transient operating conditions. Such delays can cause the reductant delivery system to be out of phase with the NOx emissions rate, which can lead to undesirable NOx spikes at the tailpipe outlet.
Based on the above, a need exists for an SCR system that accounts for potential inaccuracies between commanded and actual reductant flow rates, as well as inherent delays associated with reductant delivery system dynamics, to reduce NOx emission spikes and improve the overall NOx conversion efficiency of the system.
The subject matter of the present application has been developed in response to the present state of the art, and in particular, in response to the problems and needs in the art that have not yet been fully solved by currently available exhaust aftertreatment systems. Accordingly, the subject matter of the present application has been developed to provide apparatus, systems, and methods for reducing NOx emissions on an SCR catalyst that overcomes at least some shortcomings of the prior art aftertreatment systems.
For example, according to one representative embodiment, an apparatus for controlling reductant dosing in an SCR catalyst system having a reductant injection system configured to inject reductant into an exhaust gas stream includes a controller, an actual reductant dosing rate module, and a reductant doser compensation module. The controller is configured to determine a reductant dosing rate command representing a desired reductant dosing rate. The actual reductant dosing rate module is configured to determine a predicted actual reductant dosing rate based at least partially on the reductant dosing rate command. The reductant doser compensation module is configured to determine a modified reductant dosing rate command based at least partially on the predicted actual reductant dosing rate. The reductant injection system injects reductant into the exhaust gas stream at a rate corresponding to the modified reductant dosing rate command.
According to some implementations, the actual reductant dosing rate module comprises a natural delay module configured to determine a natural delay compensated reductant dosing rate. The natural delay compensated reductant dosing rate can be determined by multiplying the desired reductant dosing rate by Equation 1 below. The actual reductant dosing rate module can also include a reductant doser plant module configured to determine the predicted actual reductant dosing rate based at least partially on the natural delay compensated reductant dosing rate. In some instances, the predicted actual reductant dosing rate is determined by multiplying the natural delay compensated reductant dosing rate by Equation 2 below. In certain implementations, the apparatus includes at least one look-up table that is accessible by the reductant doser plant module. The at least one look-up table can include experimentally obtained data sets from which the steady state gain offset parameter δ, the first time constant parameter α, and the second time constant parameter β of Equation 2 are obtained.
According to some implementations, the reductant dower compensation module includes an inverted reductant doser plant module configured to determine the modified reductant dosing rate command by multiplying the predicted actual reductant dosing rate by Equation 3 below. In certain implementations, the apparatus includes at least one look-up table that is accessible by the inverted reductant doser plant module. The at least one look-up table can include experimentally obtained data sets from which the steady state gain offset parameter δ, the first time constant parameter α, and the second time constant parameter β of Equation 3 are obtained.
In certain implementations, the modified reductant dosing rate command compensates for (i) discrepancies between the reductant dosing rate command and the actual reductant dosing rate of the reductant injected into the exhaust gas stream; and (ii) any physical delays of the reductant injection system.
According to another representative embodiment, a method for controlling reductant dosing in an SCR catalyst system having a reductant injector configured to inject reductant into an exhaust gas stream includes several operative actions. For example, the method can include determining a reductant dosing rate command representing a desired reductant dosing rate. The method can also include determining a predicted actual reductant dosing rate corresponding to the reductant dosing rate command and determining a modified reductant dosing rate command based at least partially on the predicted actual reductant dosing rate. Additionally, the method includes injecting reductant into the exhaust gas stream at a rate corresponding to the modified reductant dosing rate command.
In some implementations, the method includes modifying the reductant dosing rate command to compensate for a natural delay of the SCR catalyst system. Moreover, the predicted actual reductant dosing rate can be based at least partially on the natural delay of the SCR catalyst system.
In certain instances, the modified reductant dosing rate command is based at least partially on the difference between a predetermined actual reductant dosing rate resulting from the reductant dosing rate command and the desired reductant dosing rate. In yet certain instances, the modified reductant dosing rate command is based at least partially on a predetermined time constant between the reductant dosing rate command and an injection of reductant corresponding to the reductant dosing rate command. Additionally, in some instances, the modified reductant dosing rate command is based at least partially on a first predetermined time constant and second predetermined time constant, wherein the first predetermined time constant comprises a micro-controller pure delay and the second predetermined time constant comprises an actuation system dynamics delay. In some implementations, the modified reductant dosing rate command is a function of Equation 3 below, where δ is a predetermined steady state gain offset between the reductant dosing rate command and an actual injection rate of reductant corresponding to the reductant dosing rate command, α is a first predetermined time constant based at least partially on the time delay between the reductant dosing rate command and the actual injection of reductant corresponding to the reductant dosing rate command, and β is a second predetermined time constant based at least partially on the time delay between the reductant dosing rate command and the actual injection of reductant corresponding to the reductant dosing rate command. In some instances, α is a first predetermined time constant corresponding to the high corner frequency of the actuation system frequency response characteristic at the commanded dosing rate, and β is a second predetermined time constant corresponding to the low corner frequency of the actuation system frequency response characteristic at the commanded dosing rate.
In another representative embodiment, a system for controlling reductant dosing in an SCR catalyst system of an engine system includes an internal combustion engine, an SCR catalyst, a reductant injector and a controller. The controller includes a reductant dosing rate command module configured to determine a reductant dosing rate command corresponding to a desired reductant dosing rate. Additionally, the controller includes an actual reductant dosing rate module configured to determine a predicted actual reductant dosing rate corresponding to the reductant dosing rate command. The predicted actual reductant dosing rate is a function of the natural delay of the reductant injection system. The controller also includes a reductant doser compensation module configured to determine a modified reductant dosing rate command representing a modified reductant dosing rate. The modified reductant dosing rate is a function of an accuracy and a time delay of the injection system. In some instances, the accuracy includes the difference between a predetermined actual reductant dosing rate resulting from the reductant dosing rate command and the desired reductant dosing rate. In yet some instances, the time delay includes a predetermined time constant between the reductant dosing rate command to inject reductant into the exhaust gas stream at the desired dosing rate and the actual injection of the reductant. The reductant injection system is configured to inject reductant into the exhaust gas stream at the modified reductant dosing rate according to the modified reductant dosing rate command such that the actual reductant dosing rate is substantially equal to desired reductant dosing rate.
According to some implementations, the actual reductant dosing rate module determines the predicted actual dosing rate by multiplying the desired reductant dosing rate by Equation 1 below and Equation 2 below. In some implementations, the reductant doser compensation module determines the modified reductant dosing rate associated with the modified reductant dosing rate command by multiplying the predicted actual dosing rate by Equation 3 below. wherein the first time constant parameter α comprises the inverse of a higher corner frequency of a normalized reductant dosing frequency response characteristic at the commanded reductant dosing rate, and the second time constant parameter β comprises the inverse of a lower corner frequency of the normalized reductant dosing frequency response characteristic at the commanded reductant dosing rate.
In certain instances of the system, the higher the desired reductant dosing rate, the greater the impact of the accuracy of the injection system on the modified reductant dosing rate command and the lesser the impact of the time delay of the injection system on the modified reductant dosing rate command. Similarly, the lower the desired reductant dosing rate, the lesser the impact of accuracy of the injection system on the modified reductant dosing rate command and the greater the impact of the time delay of the injection system on the modified reductant dosing rate command.
Reference throughout this specification to features, advantages, or similar language does not imply that all of the features and advantages that may be realized with the subject matter of the present disclosure should be or are in any single embodiment. Rather, language referring to the features and advantages is understood to mean that a specific feature, advantage, or characteristic described in connection with an embodiment is included in at least one embodiment of the present disclosure. Thus, discussion of the features and advantages, and similar language, throughout this specification may, but do not necessarily, refer to the same embodiment.
Furthermore, the described features, advantages, and characteristics of the subject matter of the present disclosure may be combined in any suitable manner in one or more embodiments. One skilled in the relevant art will recognize that the subject matter may be practiced without one or more of the specific features or advantages of a particular embodiment. In other instances, additional features and advantages may be recognized in certain embodiments that may not be present in all embodiments. These features and advantages will become more fully apparent from the following description and appended claims, or may be learned by the practice of the subject matter as set forth hereinafter.
In order that the advantages of the subject matter may be more readily understood, a more particular description of the subject matter briefly described above will be rendered by reference to specific embodiments that are illustrated in the appended drawings. Understanding that these drawings depict only typical embodiments of the subject matter and are not therefore to be considered to be limiting of its scope, the subject matter will be described and explained with additional specificity and detail through the use of the drawings, in which:
Many of the functional units described in this specification have been labeled as modules, in order to more particularly emphasize their implementation independence. For example, a module may be implemented as a hardware circuit comprising custom VLSI circuits or gate arrays, off-the-shelf semiconductors such as logic chips, transistors, or other discrete components. A module may also be implemented in programmable hardware devices such as field programmable gate arrays, programmable array logic, programmable logic devices or the like.
Modules may also be implemented in software for execution by various types of processors. An identified module of executable code may, for instance, comprise one or more physical or logical blocks of computer instructions, which may, for instance, be organized as an object, procedure, or function. Nevertheless, the executables of an identified module need not be physically located together, but may comprise disparate instructions stored in different locations which, when joined logically together, comprise the module and achieve the stated purpose for the module.
Indeed, a module of executable code may be a single instruction, or many instructions, and may even be distributed over several different code segments, among different programs, and across several memory devices. Similarly, operational data may be identified and illustrated herein within modules, and may be embodied in any suitable form and organized within any suitable type of data structure. The operational data may be collected as a single data set, or may be distributed over different locations including over different storage devices.
Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
Furthermore, the described features, structures, or characteristics of the subject matter described herein may be combined in any suitable manner in one or more embodiments. In the following description, numerous specific details are provided, such as examples of controls, structures, algorithms, programming, software modules, user selections, network transactions, database queries, database structures, hardware modules, hardware circuits, hardware chips, etc., to provide a thorough understanding of embodiments of the subject matter. One skilled in the relevant art will recognize, however, that the subject matter may be practiced without one or more of the specific details, or with other methods, components, materials, and so forth. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the disclosed subject matter.
Within the internal combustion engine 11, the air from the atmosphere is combined with fuel to power the engine. Combustion of the fuel and air produces exhaust gas that is operatively vented to the exhaust manifold 16. From the exhaust manifold 16, a portion of the exhaust gas may be used to power the turbocharger turbine 18. The turbine 18 drives the turbocharger compressor 20, which may compress at least some of the air entering the air inlet 12 before directing it to the intake manifold 14 and into the compression chambers of the engine 11.
The exhaust gas after-treatment system 100 is coupled to the exhaust manifold 16 of the engine 11. At least a portion of the exhaust gas exiting the exhaust manifold 16 can pass through the exhaust after-treatment system 100. In certain implementations, the engine system 10 includes an exhaust gas recirculation (EGR) valve (not shown) configured to open to allow a portion of the exhaust gas to recirculate back into the compression chambers for altering the combustion properties of the engine 11.
Generally, the exhaust gas after-treatment system 100 is configured to remove various chemical compound and particulate emissions present in the exhaust gas received from the exhaust manifold 16 and not recirculated back into the engine 11. As illustrated in
The oxidation catalyst 140 can be any of various flow-through, diesel oxidation catalysts (DOC) known in the art. Generally, the oxidation catalyst 140 is configured to oxidize at least some particulate matter, e.g., the soluble organic fraction of soot, in the exhaust and reduce unburned hydrocarbons and CO in the exhaust to less environmentally harmful compounds. For example, the oxidation catalyst 140 may sufficiently reduce the hydrocarbon and CO concentrations in the exhaust to meet the requisite emissions standards.
The particulate filter 142 can be any of various particulate filters known in the art configured to reduce particulate matter concentrations, e.g., soot and ash, in the exhaust gas to meet requisite emission standards. The particulate filter 142 can be electrically coupled to a controller, such as controller 130, that controls various characteristics of the particulate filter, such as, for example, the timing and duration of filter regeneration events. In some implementations, the particulate filter 142 and associated control system are similar to, or the same as, the respective particulate filters and control systems described in U.S. patent application Ser. Nos. 11/227,320 (filed Sep. 15, 2005); 11/227,403 (filed Sep. 15, 2005); 11/227,857 (filed Sep. 15, 2005); and 11/301,998 (filed Dec. 13, 2005), which are incorporated herein by reference.
The SCR system 150 can be similar to the SCR systems described in U.S. patent application Ser. Nos. 12/112,500; 12/112,622; 12/112,678; and 12/112,795, each filed Apr. 30, 2008, U.S. Provisional Application Nos. 61/120,283; 61/120,297; and 61/120,319, each filed Dec. 5, 2008 (hereinafter “incorporated U.S. patent applications”), which are each incorporated herein by reference. For example, the SCR system 150 includes a reductant delivery system 151 that includes a reductant source 170, pump 180 and delivery mechanism 190. The reductant source 170 can be a container or tank capable of retaining a reductant, such as, for example, ammonia (NH3), urea, diesel fuel, or diesel oil. The reductant source 170 is in reductant supplying communication with the pump 180, which is configured to pump reductant from the reductant source to the delivery mechanism 190. The delivery mechanism 190 can include a reductant injector schematically shown at 192 positioned upstream of the SCR catalyst 152. The injector is selectively controllable to inject reductant directly into the exhaust gas stream prior to entering the SCR catalyst 152. In some embodiments, the reductant can either be ammonia or urea, which decomposes to produce ammonia. The ammonia reacts with NOx in the presence of the SCR catalyst 152 to reduce the NOx to less harmful emissions, such as N2 and H2O. The SCR catalyst 152 can be any of various catalysts known in the art. For example, in some implementations, the SCR catalyst 152 is a vanadium-based catalyst, and in other implementations, the SCR catalyst is a zeolite-based catalyst, such as a Cu-Zeolite or a Fe-Zeolite catalyst. In one representative embodiment, the reductant is aqueous urea and the SCR catalyst 152 is a zeolite-based catalyst.
The AMOX catalyst 160 can be any of various flow-through catalysts configured to react with ammonia to produce mainly nitrogen. Generally, the AMOX catalyst 160 is utilized to remove ammonia that has slipped through or exited the SCR catalyst 152 without reacting with NOx in the exhaust. In certain instances, the system 10 can be operable with or without an AMOX catalyst. Further, although the AMOX catalyst 160 is shown as a separate unit from the SCR catalyst 152, in some implementations, the AMOX catalyst can be integrated with the SCR catalyst, e.g., the AMOX catalyst and the SCR catalyst can be located within the same housing.
As shown in
Although the exhaust after-treatment system 100 shown includes one of an oxidation catalyst 140, particulate filter 142, SCR catalyst 152, and AMOX catalyst 160 positioned in specific locations relative to each other along the exhaust flow path, in other embodiments, the exhaust after-treatment system may include more than one of any of the various catalysts positioned in any of various positions relative to each other along the exhaust flow path as desired. Further, although the oxidation catalyst 140 and AMOX catalyst 160 are non-selective catalysts, in some embodiments, the oxidation and AMOX catalysts can be selective catalysts.
The controller 130 controls the operation of the engine system 10 and associated sub-systems, such as the engine 11 and exhaust gas after-treatment system 100. The controller 130 is depicted in
The controller 130 includes various modules for controlling the operation of the engine system 10. For example, the controller 130 includes one or more modules (not shown) for controlling the operation of the particulate filter 142 as described above. The controller 130 also includes one or more modules for controlling the operation of the SCR system 150. The controller 130 further includes one or more modules (not shown) for controlling the operation of the engine 11. Additionally, in the event the oxidation catalyst 140 and AMOX catalyst 160 are selectively controllable, the controller 130 can include one or more modules (not shown) for controlling the operation of the respective oxidation and AMOX catalysts.
In operation, the controller 130 is configured to command the reductant delivery mechanism 190 to inject reductant into the exhaust stream at a specified reductant dosing rate based on a commanded reductant dosing rate. More specifically, in certain embodiments, the controller 130 determines a modified reductant dosing rate command 240 representing a modified reductant dosing rate and communicates the command 240 to the reductant delivery mechanism 190.
Referring to
The reductant delivery system 150 accounts for possible inaccuracies in the actual reductant dosing rate and physical delays in the actual injection of reductant by compensating for the commanded reductant dosing rate such that the actual reductant dosing rate and actual reductant injection timing corresponds with the commanded reductant dosing rate and commanded injection timing. Referring to
The actual urea dosing rate module 210 receives a commanded reductant dosing rate 202 and determines a predicted actual urea dosing rate 160 that would result from the commanded reductant dosing rate. The commanded reductant dosing rate 202 can be generated by a module of a controller, such as module 200 of controller 130, in any of various ways based on any of various parameters and operating conditions, such as described in the incorporated U.S. patent applications. Referring to
The natural delay module 300 modifies the commanded reductant dosing rate represented by the reductant dosing rate command 202 to obtain a natural delay compensated reductant dosing rate 310. The natural delay compensated reductant dosing rate 310 account for the natural or inherent delay of the engine control system through application of the following equation:
e−sT
where s is a complex variable used for Laplace transforms and Td is the pure delay of the system. The complex variable s can be expressed as σ+jω, where σ represents the amplitude and ω represents the frequency of a sinusoidal wave associated with a given urea dosing rate input. The pure delay of any control system is the delay associated with, among other things, the finite velocity of electronic signals along transmission paths, and can vary from control system to control system. As is well known in the art, the pure delay of a system, e.g., Td, can be determined through simple experimentation. The natural delay compensated reductant dosing rate 310 is obtained by multiplying the commanded reductant dosing rate 200 by the value obtained through application of Equation 1. Generally, the higher the pure delay of the system, the lower the natural delay compensated reductant dosing rate 310, i.e., the greater the reduction of the commanded reductant dosing rate 200.
The reductant doser plant module 320 receives the natural delay compensated reductant dosing rate 310 from the natural delay module 300 and modifies it to obtain a predicted actual reductant dosing rate 220. The natural delay compensated reductant dosing rate 310 is modified through application of a reductant doser plant model P(s) defined by the following equation:
where s is a is a complex variable used for Laplace transforms as described above, and δ, α, and β are experimentally obtained parameters. The reductant doser plant module 320 calculates the actual reductant dosing rate 220 by multiplying the natural delay compensated reductant dosing rate 310 by the reductant doser plant model P(s) value.
The steady state gain offset parameter δ can be obtained by comparing the commanded dosing rate versus the actual measured dosing rate.
Alternatively, the steady state gain offset parameter δ can be determined from experimentally obtained frequency response characteristic plots of the reductant delivery system 151. The frequency response characteristic plots of the reductant delivery system 151 can be obtained using controls system response measurement techniques commonly known in the art. In certain implementations, the frequency response characteristic plots each include a magnitude plot and a phase plot representing the reductant delivery system response signal versus normalized signal frequency. The magnitude plot can be modeled as a function of the steady state gain offset parameter δ according to 20*log 10(δ). Accordingly, steady state gain offset parameter δ is obtainable with knowledge of the magnitude plot of the system response signal.
The time constant parameters α and β can be obtained from experimentally obtained data concerning the actual dosing delays associated at specific commanded reductant dosing rates. For example, the time constant parameters α and β can be determined from the frequency response characteristic plot of the reductant delivery system 151. More specifically, the time constant parameter α for a given commanded reductant dosing rate is equal to the inverse of the higher corner frequency of the normalized reductant dosing frequency response magnitude plot at the given commanded reductant dosing rate. Similarly, the time constant parameter β for a given commanded reductant dosing rate is equal to the inverse of the lower corner frequency of the normalized reductant dosing frequency response magnitude plot at the given commanded reductant dosing rate. Stored data regarding pre-obtained normalized reductant dosing frequency response characteristic plots for possible commanded reductant dosing rates can be accessible by the reductant doser plant module 320 and used to determine the predicted actual reductant dosing rate 220.
The test data shown in
Referring to
where s, δ, α, and β represent parameters as described above in relation Equation 2. The reductant doser compensation module 230 calculates the modified reductant dosing rate by multiplying the actual reductant dosing rate 220 by the inverse reductant doser plant model G(s) value. The parameters δ, α, and β of Equation 3 can be experimentally obtained and stored in the same manner as described above. In certain implementations, the parameters δ, α, and β of Equation 3 are determined from the same stored look-up table as described above in relation to Equation 2.
The schematic flow chart diagrams and method schematic diagrams described above are generally set forth as logical flow chart diagrams. As such, the depicted order and labeled steps are indicative of representative embodiments. Other steps and methods may be conceived that are equivalent in function, logic, or effect to one or more steps, or portions thereof, of the methods illustrated in the schematic diagrams. Additionally, the format and symbols employed are provided to explain the logical steps of the schematic diagrams and are understood not to limit the scope of the methods illustrated by the diagrams. Although various arrow types and line types may be employed in the schematic diagrams, they are understood not to limit the scope of the corresponding methods. Indeed, some arrows or other connectors may be used to indicate only the logical flow of a method. For instance, an arrow may indicate a waiting or monitoring period of unspecified duration between enumerated steps of a depicted method. Additionally, the order in which a particular method occurs may or may not strictly adhere to the order of the corresponding steps shown.
According to one exemplary method 700 for controlling reductant dosing in an SCR catalyst system shown in
Based at least partially on the actual reductant dosing rate 220, the inverted reductant doser plant module 400 of the reductant doser compensation module 230 determines 740 the modified reductant rate commanded by the modified reductant dosing rate command 240 through application of Equation 3 above, such as by multiplying the actual reductant dosing rate by the value obtained from Equation 3. Calculating the value of Equation 3 can include accessing the system parameters δ, α, and β from a memory located on or accessible by the controller 130.
The modified reductant dosing rate command 240 representing the modified reductant dosing rate is communicated 750 to the reductant delivery mechanism 190 of the SCR system 150. The reductant delivery mechanism 190 then injects 760 reductant into the exhaust stream through the injector 192 at a rate corresponding to the modified reductant dosing rate command 240.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. For example, various specific embodiments of the disclosed apparatus, system, and method are described in the several appended claims below. The embodiments described above and in the following claims are to be considered in all respects only as illustrative and not restrictive.
Several specific embodiments of the apparatus, system, and method of the present disclosure are defined according to the following appended claims:
This application claims the benefit of U.S. Provisional Patent Application No. 61/120,304, filed Dec. 5, 2008, which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4314345 | Shiraishi et al. | Feb 1982 | A |
5552128 | Chang et al. | Sep 1996 | A |
5809775 | Tarabulski et al. | Sep 1998 | A |
6109024 | Kinugasa et al. | Aug 2000 | A |
6125629 | Patchett | Oct 2000 | A |
6182443 | Jarvis et al. | Feb 2001 | B1 |
6266955 | Liang et al. | Jul 2001 | B1 |
6269633 | van Nieuwstadt et al. | Aug 2001 | B1 |
6295809 | Hammerle et al. | Oct 2001 | B1 |
6311484 | Roth et al. | Nov 2001 | B1 |
6375828 | Ando et al. | Apr 2002 | B2 |
6415602 | Patchett et al. | Jul 2002 | B1 |
6446430 | Roth et al. | Sep 2002 | B1 |
6546720 | van Nieuwstadt | Apr 2003 | B2 |
6581374 | Patchett et al. | Jun 2003 | B2 |
6662553 | Patchett et al. | Dec 2003 | B2 |
6701707 | Upadhyay et al. | Mar 2004 | B1 |
6713030 | Chandler et al. | Mar 2004 | B1 |
6742326 | Xu et al. | Jun 2004 | B2 |
6742330 | Genderen | Jun 2004 | B2 |
6829885 | Surnilla et al. | Dec 2004 | B2 |
6882929 | Liang et al. | Apr 2005 | B2 |
6892530 | Montreuil et al. | May 2005 | B2 |
6901745 | Schnaibel et al. | Jun 2005 | B2 |
6928806 | Tennison et al. | Aug 2005 | B2 |
6981368 | van Nieuwstadt et al. | Jan 2006 | B2 |
6993900 | Upadhyay et al. | Feb 2006 | B2 |
7017389 | Gouma | Mar 2006 | B2 |
7063642 | Hu et al. | Jun 2006 | B1 |
7093427 | van Nieuwstadt et al. | Aug 2006 | B2 |
7113835 | Boyden et al. | Sep 2006 | B2 |
7117046 | Boyden et al. | Oct 2006 | B2 |
7134273 | Mazur et al. | Nov 2006 | B2 |
7150145 | Patchett et al. | Dec 2006 | B2 |
7168243 | Endicott et al. | Jan 2007 | B2 |
7178328 | Solbrig | Feb 2007 | B2 |
7204081 | Yasui et al. | Apr 2007 | B2 |
7213395 | Hu et al. | May 2007 | B2 |
7263825 | Wills et al. | Sep 2007 | B1 |
7293410 | Miura | Nov 2007 | B2 |
7320781 | Lambert et al. | Jan 2008 | B2 |
7332135 | Gandhi et al. | Feb 2008 | B2 |
7485272 | Driscoll et al. | Feb 2009 | B2 |
7603846 | Lueders et al. | Oct 2009 | B2 |
7628009 | Hu et al. | Dec 2009 | B2 |
7631490 | Colignon | Dec 2009 | B2 |
7650746 | Hu et al. | Jan 2010 | B2 |
7685813 | McCarthy, Jr. | Mar 2010 | B2 |
7802419 | Doring | Sep 2010 | B2 |
7832200 | Kesse et al. | Nov 2010 | B2 |
7861518 | Federle | Jan 2011 | B2 |
7892508 | Katoh | Feb 2011 | B2 |
7950222 | Hodzen | May 2011 | B2 |
7997070 | Yasui et al. | Aug 2011 | B2 |
8020374 | Walz et al. | Sep 2011 | B2 |
8061126 | Gady et al. | Nov 2011 | B2 |
8074445 | Ofoli et al. | Dec 2011 | B2 |
20020044897 | Kakwani et al. | Apr 2002 | A1 |
20030177766 | Wang | Sep 2003 | A1 |
20030182935 | Kawai et al. | Oct 2003 | A1 |
20040098968 | van Nieuwstadt et al. | May 2004 | A1 |
20040112046 | Tumale et al. | Jun 2004 | A1 |
20040128982 | Patchett et al. | Jul 2004 | A1 |
20050260761 | Lanier et al. | Nov 2005 | A1 |
20050282285 | Radhamohan et al. | Dec 2005 | A1 |
20060086080 | Katogi et al. | Apr 2006 | A1 |
20060130458 | Solbrig | Jun 2006 | A1 |
20060144038 | Miura | Jul 2006 | A1 |
20060155486 | Walsh et al. | Jul 2006 | A1 |
20060212140 | Brackney | Sep 2006 | A1 |
20070044456 | Upadhyay et al. | Mar 2007 | A1 |
20070137181 | Upadhyay et al. | Jun 2007 | A1 |
20070137184 | Patchett et al. | Jun 2007 | A1 |
20070214777 | Allansson et al. | Sep 2007 | A1 |
20070295003 | Dingle et al. | Dec 2007 | A1 |
20080022658 | Viola et al. | Jan 2008 | A1 |
20080022659 | Viola et al. | Jan 2008 | A1 |
20080031793 | DiFrancesco et al. | Feb 2008 | A1 |
20080060348 | Robel et al. | Mar 2008 | A1 |
20080066455 | Viola et al. | Mar 2008 | A1 |
20080250774 | Solbrig | Oct 2008 | A1 |
20080250778 | Solbrig | Oct 2008 | A1 |
20080295499 | Driscoll et al. | Dec 2008 | A1 |
20090272099 | Garimella et al. | Nov 2009 | A1 |
20090272101 | Wills et al. | Nov 2009 | A1 |
20090272104 | Garimella et al. | Nov 2009 | A1 |
20090272105 | Chi et al. | Nov 2009 | A1 |
20090301066 | Sindano et al. | Dec 2009 | A1 |
20100024390 | Wills et al. | Feb 2010 | A1 |
20100024393 | Chi et al. | Feb 2010 | A1 |
20100024397 | Chi et al. | Feb 2010 | A1 |
20100028230 | Gady et al. | Feb 2010 | A1 |
20100043404 | Hebbale et al. | Feb 2010 | A1 |
20100122526 | VanderVeen et al. | May 2010 | A1 |
20100242438 | Mital | Sep 2010 | A1 |
20100242440 | Garimella et al. | Sep 2010 | A1 |
20100275583 | Farrell et al. | Nov 2010 | A1 |
20110058999 | Ettireddy et al. | Mar 2011 | A1 |
20110262329 | Ofoli et al. | Oct 2011 | A1 |
Number | Date | Country |
---|---|---|
1804378 | Jul 2006 | CN |
1809685 | Jul 2006 | CN |
1129278 | Aug 2003 | EP |
1338562 | Aug 2003 | EP |
1083979 | Jun 2004 | EP |
1431533 | Jun 2004 | EP |
1339955 | Aug 2005 | EP |
1609977 | Dec 2005 | EP |
1672192 | Jun 2006 | EP |
1712764 | Oct 2006 | EP |
10118492 | May 1998 | JP |
2002327617 | Nov 2002 | JP |
2004100700 | Apr 2004 | JP |
2007255367 | Oct 2007 | JP |
1020010043138 | May 2001 | KR |
1020030034139 | May 2003 | KR |
1020080030163 | Apr 2008 | KR |
1020100061145 | Nov 2008 | KR |
9955446 | Nov 1999 | WO |
0214657 | Feb 2002 | WO |
2004000443 | Dec 2003 | WO |
2006000877 | Jan 2006 | WO |
2007066502 | Jun 2007 | WO |
2007014649 | Aug 2007 | WO |
WO 2008009940 | Jan 2008 | WO |
Entry |
---|
PCT/US2009/042419 International Search Report and Written Opinion, Jan. 27, 2010. |
PCT/US2009/042412 International Search Report and Written Opinion, Dec. 16, 2009. |
PCT/US2009/042321 International Search Report and Written Opinion, Dec. 14, 2009. |
PCT/US2009/042335 International Search Report and Written Opinion, Dec. 14, 2009. |
PCT/US2009/042330 International Search Report and Written Opinion, Dec. 17, 2009. |
PCT/US2009/042340 International Search Report and Written Opinion, Dec. 16, 2009. |
U.S. Appl. No. 12/433,600 Notice of Allowance received Nov. 14, 2011. |
U.S. Appl. No. 12/112,500 Office Action received Apr. 15, 2011. |
U.S. Appl. No. 12/112,500 Notice of Allowance received Sep. 29, 2011. |
U.S. Appl. No. 12/112,622 Office Action received Mar. 3, 2011. |
U.S. Appl. No. 12/112,622 Notice of Allowance received Aug. 5, 2011. |
U.S. Appl. No. 12/112,678 Office Action received Feb. 7, 2011. |
U.S. Appl. No. 12/112,678 Final Office Action received Jul. 22, 2011. |
U.S. Appl. No. 12/112,678 Office Action received Sep. 30, 2011. |
U.S. Appl. No. 12/112,795 Office Action received Sep. 20, 2011. |
U.S. Appl. No. 12/433,705 Office Action received Nov. 8, 2011. |
U.S. Appl. No. 12/433,767 Office Action received Oct. 26, 2011. |
U.S. Appl. No. 12/433,730 Office Action received Oct. 7, 2011. |
PCT/US2009/042406 International Search Report and Written Opinion, Dec. 18, 2009. |
U.S. Appl. No. 12/433,586 Office Action received Oct. 24, 2011. |
U.S. Appl. No. 12/112,678 Notice of Allowance received Feb. 2, 2012. |
PCT/US2009/042409, International Search Report and Written Opinion, Nov. 25, 2009. |
PCT/US2009/042423, International Search Report and Written Opinion, Nov. 27, 2009. |
P.R. Ettireddy et al. “Surface characterization studies of TiO2 supported manganese oxide catalysts for low temperature SCR of NO with NH3” Applied Catalysis B, 76 (2007). |
D.A. Pena, et al. “Identification of Surface Species on Titania-Supported Manganese, Chromium, and Copper Oxide Low-Temperature SRC Catalysts”: Journal of Physical Chemistry B, 108 (2004) 9927-9936. |
PCT/US2010/048502, International Search Report and Written Opinion, May 23, 2011. |
PCT/US2009/067023, International Search Report and Written Opinion, Jul. 13, 2010. |
PCT/US2009/067020, International Search Report and Written Opinion, Jul. 13, 2010. |
Control of a Urea SCR Catalytic Converter System for a Mobile Heavy Duty Diesel Engine—C.M. Schar, C.H. Onder, H.P. Geering and M. Elsener—SAE 2003-01-0776, Mar. 6, 2003. |
U.S. Appl. No. 12/632,646 Notice of Allowance mailed Jun. 4, 2012. |
U.S. Appl. No. 12/433,586 Notice of Allowance mailed Jul. 12, 2012. |
U.S. Appl. No. 12/433,730 Office Action mailed May 10, 2012. |
U.S. Appl. No. 12/433,767 Notice of Allowance mailed Aug. 3, 2012. |
U.S. Appl. No. 12/767,664 Office Action mailed Aug. 3, 2012. |
U.S. Appl. No. 12/433,586 Office Action received Mar. 20, 2012. |
PCT/US2011/033767 International Search Report and Written Opinion, Feb. 8, 2012. |
U.S. Appl. No. 12/112,795 Notice of Allowance received Mar. 2, 2012. |
U.S. Appl. No. 12/433,705 Notice of Allowance received Apr. 2, 2012. |
U.S. Appl. No. 12/433,767 Office Action received Apr. 6, 2012. |
U.S. Appl. No. 12/433,730 Final Office Action mailed Oct. 9, 2012. |
Chinese Patent Application No. 200980115540.1 Office Action mailed Jun. 26, 2012. |
Number | Date | Country | |
---|---|---|---|
20100229531 A1 | Sep 2010 | US |
Number | Date | Country | |
---|---|---|---|
61120304 | Dec 2008 | US |